by Kole Krieger | Apr 3, 2025 | News
Full Article Here Today, Lumen Bioscience reported that its investigational oral biologic, LMN-201, achieved a 100% clinical cure rate of C difficile infection (CDI) in the sentinel cohort (Part A) of its RePreve clinical trial. All patients (21/21; 95% confidence...
by Kole Krieger | Nov 7, 2024 | News
New technology and innovation may help turn the corner on antibiotic resistance. The antibiotic resistance crisis poses a threat to modern medicine. Antibiotic-resistant infections have become alarmingly common, and experts warn that if nothing is done we could face a...
by Kole Krieger | Aug 6, 2024 | News, Uncategorized
View on website A biotechnology company has re-invented how biologic drugs are invented by using the patented technology to use the food algae spirulina to deliver therapeutic proteins. The technology has unlimited potential for developing biologic drugs for highly...
by admin | Mar 4, 2024 | News
Listen here
by Kole Krieger | Dec 14, 2023 | News
So…where are all the new drugs? Superbugs haunt hospitals worldwide, killing millions and costing billions in healthcare spending. To this day, infectious diseases continue to literally plague the developing world, a slow-burning humanitarian disaster. COVID taught...
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases